CHRONIC OBSTRUCTIVE PULMONARY DISEASE IS ASSOCIATED WITH CORONAVIRUS DISEASE 2019 (COVID-19)
DOI:
https://doi.org/10.32782/2786-9067-2023-25-10Keywords:
chronic obstructive pulmonary disease, COPD, Coronavirus, Covid-19.Abstract
Abstract. The course of the 2019 coronavirus disease (COVID-19) is complicated by various concomitant diseases; chronic obstructive pulmonary disease (COPD) is one of them. The purpose of this study was to investigate the impact of COPD as a potential comorbidity on the prognosis of the severe course of COVID-19. Preliminary data on Covid-19 have shown a lower prevalence of COPD than would be expected in an acute respiratory illness such as COVID-19. This fact has led to the assumption that the use of inhaled glucocorticosteroids (IGCS) can protect against infection or the development of a severe course of COVID-19. The analysis of studies conducted in different groups of patients with a severe course of Сovid-19 with comorbidity of COPD made it possible to reveal statistically significant data for improving prognostic scales of an unfavorable prognosis of the disease. Further study and application of such indicators in general clinical practice will allow timely detection of patients of risk groups for the purpose of targeted monitoring and early change or intensification of treatment tactics, including concomitant diseases.
References
Klok F.A., Boon G.J.A.M., Barco S., Endres M., Geelhoed J.J.M., Knauss S., еt al. The Post-COVID-19 Functional Status (PCFS) Scale: a tool to measure functional status over time after COVID-19. Eur. Respir. J. 2020 Jul; 56 (1): 2001494. doi: 10.1183/13993003.01494-2020.
Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020 Oct;106(19):1503-1511. doi: 10.1136/heartjnl-2020-317393.
Oscanoa TJ, Vidal X, Carvajal A, et al. Severity of SARS-COV-2 infection and angiotensin converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. Arterial Hypertension. 2020;24(3): 106-114. doi: 10.5603/AH.a2020.0013.
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr;8(4):e21. Epub 2020 Mar 11. Erratum in: Lancet Respir. Med. 2020 Jun;8(6):e54. doi: 10.1016/S2213-2600(20)30116-8
Moore N, Carleton B, Blin P, et al. Does Ibuprofen Worsen COVID-19? Drug Saf. 2020 Jul;43(7):611-614. doi: 10.1007/s40264-020-00953-0.
Giavina-Bianchi P, Aun MV, Agondi RC, et al. Debate on drugs that may aggravate COVID-19. J Allergy Clin Immunol Pract. 2020 Jul-Aug;8(7):2452-2453. doi:10.1016/j.jaip.2020.04.037.
Williamson E., Walker A., Bhaskaran K., et al. Factors associated with COVID-19 – related death using OpenSAFELY. Nature. 2020; 584: 430-436.
Yang J., Zheng Y., Gou X., et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int. J. Infect. Dis. 2020; 94: 91-95. doi: 10.101
Khateri S, Mohammadi H, Khateri R, et al. The Prevalence of Underlying Diseases and Comorbidities in COVID-19 Patients; an Updated Systematic Review and Meta-analysis. Arch Acad Emerg Med. 2020 Sep 12;8(1):e72.
Hattab Y., Alhassan S., Balaan M., Lega M., Singh A. C., Chronic obstructive pulmonary disease. Crit. Care Nurs. Q. 2020. 39, 124-130.
Waszczykowska R., Węgierska M., Drygała R., Pawliczak R., Astma, przewlekła obturacyjna choroba płuc (POChP), zespół współistnienia astmy i POChP a ryzyko ciężkiego przebiegu COVID-19. Pol. J. Allergol. 2021. 8, 21-30. 12. Джерело: https://compendium.com.ua/uk/tutorials-uk/vnutrishnya-meditsina/3-rozdil-zakhvoriuvannia-orhaniv-dykhannia/3-3-hronichne-obstruktivne-zahvoryuvannya-legen/
Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020 Jul 9;383(2):120-128. doi: 10.1056/NEJMoa2015432. Epub 2020 May 21.
Vasarmidi E, Tsitoura E, Spandidos DA, et al. Pulmonary fibrosis in the aftermath of the COVID-19 era (Review) Exp Ther Med. 2020;20(3):2557–2560. doi: 10.3892/etm.2020.8980.
Ye q., Wang B., Mao J., 2020. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J. Infect. 80, 607-613.
Rothan H. A., Byrareddy S. N., 2020. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun.109, https://www.ncbi.nlm.nih.gov/pmc/arti-cles/PMC7127067/
Yang J. M., Koh H. Y., Moon S. Y., Yoo I. K., Ha E. K., You S., Kim S. Y., Yon D. K., Lee S. W., 2020a. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. J. Allergy Clin. Immunol. 146, 790-798.
Ahrenfeldt L.J., Nielsen C. R., Möller S., Christesen K., Lindahl-Jacobsen R., 2020. Burden and prevalence of risk factors for severe Covid-2019 disease in the ageing European population – ASHARE-based analysis. Res Sq., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491580/.
Beltramo G., Cottenet J., Mariet A. S., Georges M., Piroth L., Tubert-Bitter P., Bonniaud P., Quantin C., 2021., Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study, Eur. Resp. J., https://pubmed.ncbi.nlm.nih.gov/34016619/.
Halpin D. M. G., Faner R., Sibila O., Badia J. R., Agusti A., 2020a. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir. Med. 8, 436-438.
G. Lippi, B. M.L. Henry. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (Covid-2019) Respiratory Medicine Vol. 167, 105941, June 2020 DOI:https://doi.org/10.1016/j.rmed.2020.105941 22. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease – GOLD. Report 2023. 193 р.
Deslée G., Zysman M., Burgel P. R., Perez T. Boyer L., Gonzalez J., Roche N., 2020., Chronic obstructive pulmonary disease and the COVID-19 pandemic: Reciprocal challenges. and COPD. Respir Med Res. 78, https://pubmed.ncbi.nlm.nih.gov/32498023/.
Halpin D. M. G., Faner R., Sibila O., Badia J. R., Agusti A., 2020a. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir. Med. 8, 436-438.
Alqantani J. S., Oyelade T., Aldhahir A. M., Alghamdi S. M., Almehmadi M., Alqahtani A. S., Quaderi S., Mandal S., Hurst J. R., 2020. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One 15, https://pubmed.ncbi.nlm.nih.gov/32392262/.
Simons S. O., Hurst J. R., Miravitlles Frits M., Franssen M. E., Janssen D. J. A., Papi A., Duiverman M. Ll., Kerstjens H. A. M., 2020. Caring for patients with COPD and COVID-19: a viewpoint to spark discussion. Thorax 75, https://www.sciencedirect.com/science/arti-
cle/pii/S1534580720304019
Zhao Q., Meng M., Kumar R., Wu Y., Jiaofeng Huang J., Lian N., Deng Y., Li s., 2020. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J. Med. Virol., https://onlineli-brary.wiley.com/doi/10.1002/jmv.25889.
Leung J. M., Yang C. H. X., Tam A., Shaipanich T., Hackett T. L., Singhera G. K.,. Dorscheid D. R., Sin D. D., 2020. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur. Respir. J. 55, https://erj.ersjournals.com/content/ear-ly/2020/03/26/13993003.00688-2020.
Smith J. C., Sausville E. L., Girish V., Yuan M. L., Vasudevan A., John K. M., Sheltzer J. M., 2020. Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE-2 in the respiratory tract. Dev. Cell 53, 514-529.
Hsu A. C., Parsons K., Moheimani F., Knight D.A., Hansbro P. M., Fujita T., Wark P. A., 2016. Impaired antiviral stress granule and IFN-beta enhanceosome formation enhances susceptibility to influenza infection in chronic obstructive pulmonary disease epithelium. Am. J. Respir. Cell Mol. Biol. 55, 117-127.
Higham A., MathioudAkis A., Vestbo J., Singh D., 2020. COVID-19 and COPD: a narrative review of the basic science and clinical outcomes. Andrew Eur. Respir. Rev. 29, https://pubmed.ncbi.nlm.nih.gov/33153991/.
Higham A., Singh D., 2020. Increased ACE-2 expression in bronchial epithelium of Copd patients who are overweight. Obesity 28, 1586-1589.
Saheb Sharif-Askari N., Saheb Sharif-Askari F., Alabed M., Temsah M. H., Al Heialy S., Hamid Q., Halwani R., 2020. Airways expression of SARS-CoV-2 receptor, ACE-2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD. Mol. Ther. Meth. Clin. Dev. 18, 1-6.
Kasahara Y., Tuder R. M., Cool C. D., Lynch D. A., Flores S. C., Voelkel N. F., 2001. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am. J. Respir. Crit. Care Med. 163, 737-744
Singh D, Agusti A, Martinez FJ, et al. Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. Am J Respir Crit Care Med 2022; 206(1): 17-24.
Singh D., Roche N., Halpin D., Agusti A., Wedziha D. A., Martinez F.J. _ Modern controversies regarding the pharmacological treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2016; 194: 541 – 549.
Agusti A, Fabbri L.M., Singh D., Westbo J., Chelli B., Fransen FME and others. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J 2018; 52: 1801219.
Dutkowska A., Antczak A., 2016. Standardy leczenia POChP. Pulmonologia, Medycyna po Dyplomie, https://podyplomie.pl/medycyna/23780,standardy-leczenia-pochp.
Halpin D. M. G., Singh D., Hadfield R. M., 2020b. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur. Respir. J. 55.
Schultze A., Walker A.J., MacKenna B. et al. (2020) Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. The Lancet, Sept. 24. DOI:https://doi.org/10.1016/S2213-2600(20)30415-X.
Wang L., Foer D., Bates D. W., Boyce J. A., Zhou L., 2020. Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19. J. Allergy Clin. Immunol. 146, 808-812.
